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THE oncolytic agent, bleomycin (BLM),
is unusual in that bone marrow depression
is a very rare complication during clinical
use (Clinical Screening Co-operative Group
of the E.O.R.T.C., 1970). Cytogenetic
changes in marrow cells may, however, be
produced (Bornstein et al., 1971). Further-
more, studies in the rat have shown that
BLM may be administered daily at high
dose levels for a prolonged period of time
without causing significant changes in
the peripheral blood picture (Matsuda
et al., 1968). One reason for the low
haemopoietic toxicity seems to be that,
following intravenous administration of
BLM to the rat, the level of drug in the
marrow does not reach high values,
possibly due to the presence of some
BLM-inactivating enzyme (Umezawa,
1971).
In tissue culture, the sensitivity of a
number of mammalian cell lines to BLM
has been measured by Terasima and co-
workers (1972). The dose-response curve
for short period exposure (1-2 hours) is
characteristically biphasic, with the in-
flexion occurring at about 5 ,ug/ml, and
at a surviving fraction between 0-3 and
0 6. At higher doses than this the D37
is approximately 60 ,ug/ml. Using syn-
chronous cultures of Chinese hamster
ovary cells, Barranco and Humphrey
(1971) have demonstrated changes in
sensitivity to BLM at different phases of
the cell cycle (in the order mitosis (most
sensitive), G2, S, G1).
Such variations in sensitivity during
the cell cyclegivegrounds forthepostulate
that the unusual proliferation character-
istics of the bone marrow stem cell may
be a contributory factor in the low sensi-
tivity of the marrow to BLM toxicity.
Experiments have therefore been car-
ried out in vivo to measure the effect
of BLM on the survival of spleen colony-
forming units (CFU-S) in the mouse, both
in normal animals and in animals in which
the proportion of CFU-S in the prolifera-
tive cycle was greatly increased. Incuba-
tion of marrow with BLM in vitro was
also carried out to determine the sensiti-
vity of CFU-S when brought into contact
with defined levels of the drug.
MATERIALS AND METHODS
A freeze-dried plug of bleomycin batch
no. F-1921 was initially dissolved in sterile
water and then diluted either in 0 9% saline
for intravenous injection into mice, or in
Hank's solution for incubation experiments.
The mice used were males of either the
BalbC or C57 BL inbred lines, weighing
21-26 g and supplied by the Institute of
Cancer Research, London.
Increased proliferation of CFU-S was
induced by the use of S. typhosa endotoxin
(Difco Laboratories) as described by Eaves
and Bruce (1972). In the present study,THE SENSITIVITY TO BLEOMYCIN OF CFU-S IN MICE
50 ,ug/mouse of endotoxin was injected intra-
peritoneally 20 hours before either BLM
administration or the removal of marrow for
incubation. At this time, the total nucleated
cell count/femur and the CFU-S/femur were
depressed to about 50% of normal in both
strains of mice, thus agreeing with the
observations of Eaves and Bruce (1972).
In one experiment, regenerating marrow
was used instead ofendotoxintreated marrow.
A group of C57 BL mice was given 750 rad
whole body irradiation and shortly after-
wards each received marrow cells equivalent
to one-third of a femur from normal mice of
the same strain. BLM was administered 7
days later and the animals killed after a
further 24 hours for marrow transplantation.
The concentration of CFU-S/femur in the
control regenerating marrow group was about
7% ofthat in normal control mice.
The assay for CFU-S was carried out by a
method similar to that described by Till and
McCulloch (1961). For in vivo experiments,
the marrow from 6 femora was aspirated from
matched groups of 3 mice which had received
BLM 24 hours previously. Marrow suspen-
sions were prepared and diluted in ice-cold
Hank's solution for injection into recipients.
Control recipients received 7-5 x 104 nucle-
ated cells from either normal control or endo-
toxin control donors, in each case resulting in
about 10-12 colonies/spleen. Groups of 8
recipientsweregiven750rad wholebodyirradi-
ation from a 137Cs unit about 16 hours before
bone marrow transplantation. Spleens were
removed 8 days after marrow transplantation,
fixed in Bouin's fluid and counted by two
independent observers. The spleen colony
count in mice receiving no bone marrow
varied between 0 3 and 0-6 colonies/spleen.
Incubation procedure.-Marrow was aspir-
ated from 6 femora into 7 ml of ice-cold
Hank's solution. The suspension was then
divided into 3 aliquots of 2 ml each, and a
count carried out on the remaining volume.
The appropriate dose ofBLM was then added
to two of the aliquots in a small volume of
Hank's solution, the third aliquot remaining
as a control. These suspensions were incu-
bated at 37°C for 30 min and at the end
of this period, 20 ml of ice-cold Hank's
solution was added to each, followed by
centrifugation for 8 min at 1000 rev/min.
The supernatant was discarded and the cells
re-suspended in ice-cold Hank's solution
before dilution and injection into recipients.
RESULTS
BLM in vivo (Fig. 1)
Similar results were obtained for the
two strains of mice used and are shown on
the same graph. It may be seen that in
the normal mouse even the high doses of
BLM had little effect on CFU-S. Follow-
ing endotoxin (or in regenerating marrow),
however, the depression of CFU-S was
increased considerably, reaching mean
surviving fraction values of 0 5 at 50 mg/
kg and 0415 at 200 mg/kg.
BLM in vitro (Fig. 2)
Again, there appeared to be an
increased sensitivity to BLM in marrow
from endotoxin-pretreated mice. For
BalbC mice the increase was apparently
more pronounced at the low dose, due
perhaps to a more pronounced initial slope
of the dose-response curve for CFU-S
following endotoxin.
DISCUSSION
It is clear from these results that even
doses of BLM approaching the LD50
(,200 mg/kg) have little effect on CFU-S
at 24 hours after administration to normal
mice. In rapidly proliferating CFU-S the
effect is more pronounced, although there
is only a 500% depression at 50 mg/kg.
This dose is to be compared with the dose
of 30 mg per patient normally given
during a single administration in clinical
use, i.e., higher by a factor of x 100. The
blood clearance following intravenous
administration of this agent is rapid, the
level falling by a factor of 10 over a period
of one hour, and then rather more slowly
(Fujita and Kimura, 1970). It is possible,
therefore, that BLM, as a proliferation-
dependent cytotoxic agent, may be con-
siderably more toxic when given in a
series of doses, leading to significant
CFU-S depression at a much lower total
dose. Studies are at present being carried
out in this laboratory into the time
response of CFU-S following single dose
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FIG. 1. Change in CFU-S/femur with dose of BLM administered 24 hours previously. Closed symbols control mice; open symbols mice given endotoxin 20 hours before BLM; round symbols -BalbC mice; square symbols C.57 BL mice; crosses regenerating marrow in C57 BL mice. Error bars represent ± one standard error of the mean.
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FIGT. 2. Change in CFU-S with dose of BL-M for 30 min incubation at 37 C. Closed symbols-
marrow from control mice; open symbols-marrow from mice given endotoxin 20 hours pre-
viously; rouind symbols BalbC mice; square symbols C57 BL mice. Error bars represeint - one
standard error of the mean.
BLM andl also into the effect of various
drug fractionation patterns.
The results in vitro confirm that
CFU-S in cycle are more sensitive to BLM
than those out of the proliferative cycle.
Cells from normal donors are only slightly
depleted by BLM at 50 ,ag/ml, and the
further depression between 50 and 200
/tg/ml is by less than a factor of 3. In
comparison with the D37 of 60 ,ag/ml for
other mammalian cell types (Terasima et
al., 1972), this is a very shallow dose-
response curve. For enidotoxin pre-
treated CFU-S in BalbC mice, however,
the survival of 0 3-0 4 at 50 ,ug/ml is not
too different from the range of values
reported by Terasima et al. (1972), al-
though the further depression at 200 ,ug/
ml is again very small. It may be con-
cluded therefore that the sensitivity of
CFU-S to BLM in vitro appears to be
lower than that found for various other
mammalian cell types.
Whilst confirming that the bone-
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marrow stem cells are indeed relatively
resistant to BLM, these results indicate a
clear proliferation dependence. It may
well be advisable therefore to use some
degree of caution when administering the
agent clinically to patients whose marrow
is depressed following previous chemo-
therapy or radiotherapy.
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